EP0098110B1
(en)
*
|
1982-06-24 |
1989-10-18 |
NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTD |
Long-acting composition
|
JPS59196824A
(ja)
*
|
1983-04-21 |
1984-11-08 |
Kowa Co |
吸着防止剤
|
JPS60176586A
(ja)
*
|
1984-02-21 |
1985-09-10 |
Sanwa Kagaku Kenkyusho:Kk |
新規な修飾ウロキナ−ゼ、その製法並びにこれを含有する血栓溶解剤
|
GB8430252D0
(en)
*
|
1984-11-30 |
1985-01-09 |
Beecham Group Plc |
Compounds
|
US4732863A
(en)
*
|
1984-12-31 |
1988-03-22 |
University Of New Mexico |
PEG-modified antibody with reduced affinity for cell surface Fc receptors
|
JPS61176532A
(ja)
*
|
1985-01-30 |
1986-08-08 |
Green Cross Corp:The |
プラスミノ−ゲンアクチベ−タ−前駆体の安定化方法
|
US4766106A
(en)
*
|
1985-06-26 |
1988-08-23 |
Cetus Corporation |
Solubilization of proteins for pharmaceutical compositions using polymer conjugation
|
US4844897A
(en)
*
|
1985-09-13 |
1989-07-04 |
Hiroshi Maeda |
Anti-tumor protease preparations
|
JP2514950B2
(ja)
*
|
1986-03-10 |
1996-07-10 |
エフ・ホフマン―ラ ロシユ アーゲー |
化学修飾蛋白質,その製造法および中間体
|
US4791192A
(en)
*
|
1986-06-26 |
1988-12-13 |
Takeda Chemical Industries, Ltd. |
Chemically modified protein with polyethyleneglycol
|
DK468388A
(da)
*
|
1987-08-21 |
1989-02-22 |
Wellcome Found |
Kompleks af polyethylenglycol og vaevplasminogen-aktivator, fremgangsmaade til dets fremstilling og farmaceutiske kompositioner indeholdende komplekset
|
US5162430A
(en)
*
|
1988-11-21 |
1992-11-10 |
Collagen Corporation |
Collagen-polymer conjugates
|
US5565519A
(en)
*
|
1988-11-21 |
1996-10-15 |
Collagen Corporation |
Clear, chemically modified collagen-synthetic polymer conjugates for ophthalmic applications
|
US5510418A
(en)
*
|
1988-11-21 |
1996-04-23 |
Collagen Corporation |
Glycosaminoglycan-synthetic polymer conjugates
|
US5306500A
(en)
*
|
1988-11-21 |
1994-04-26 |
Collagen Corporation |
Method of augmenting tissue with collagen-polymer conjugates
|
US5166322A
(en)
*
|
1989-04-21 |
1992-11-24 |
Genetics Institute |
Cysteine added variants of interleukin-3 and chemical modifications thereof
|
US6586222B1
(en)
|
1989-08-16 |
2003-07-01 |
Chiron Corporation |
Recombinant PR-3 and compositions thereof
|
US5843693A
(en)
*
|
1989-08-16 |
1998-12-01 |
Chiron Corporation |
Assay method for screening for inhibitors of proTNF conversion
|
US5998378A
(en)
*
|
1989-08-16 |
1999-12-07 |
Chiron Corporation |
Compositions for the inhibition of TNF hormone formation and uses thereof
|
IT1260468B
(it)
*
|
1992-01-29 |
1996-04-09 |
|
Metodo per mantenere l'attivita' di enzimi proteolitici modificati con polietilenglicole
|
US20030171292A1
(en)
*
|
1992-06-01 |
2003-09-11 |
Creasey Abla A. |
Method for using lipoprotein associated coagulation inhibitor to treat sepsis
|
US6063764A
(en)
*
|
1992-06-01 |
2000-05-16 |
Washington University & Chiron Corp. |
Method for using lipoprotein associated coagulation inhibitor to treat sepsis
|
JPH08502082A
(ja)
*
|
1992-07-02 |
1996-03-05 |
コラーゲン コーポレイション |
生体適合性ポリマー結合体
|
AU687763B2
(en)
*
|
1992-10-20 |
1998-03-05 |
Central Laboratory Of The Netherlands Red Cross Blood Transfusion Service |
Interleukin-6 receptor antagonists
|
CA2185162A1
(en)
|
1994-03-07 |
1995-09-14 |
Robert F. Halenback (Deceased) |
Compositions for the inhibition of tnf formation and uses thereof
|
US6833408B2
(en)
*
|
1995-12-18 |
2004-12-21 |
Cohesion Technologies, Inc. |
Methods for tissue repair using adhesive materials
|
US6458889B1
(en)
|
1995-12-18 |
2002-10-01 |
Cohesion Technologies, Inc. |
Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use
|
US7883693B2
(en)
*
|
1995-12-18 |
2011-02-08 |
Angiodevice International Gmbh |
Compositions and systems for forming crosslinked biomaterials and methods of preparation of use
|
ATE330644T1
(de)
*
|
1995-12-18 |
2006-07-15 |
Angiotech Biomaterials Corp |
Vernetzten polymerisatmassen und verfahren für ihre verwendung
|
JP4219985B2
(ja)
*
|
1996-07-23 |
2009-02-04 |
タノックス ファーマ ベスローテン フェンノートシャップ |
二つの共刺激経路を同時にブロックできる可溶性分子を用いたt細胞寛容の誘導
|
AU1727500A
(en)
*
|
1998-11-17 |
2000-06-05 |
Tanox, Inc. |
Bispecific molecules cross-linking itim and itam for therapy
|
US7118743B2
(en)
|
1998-11-17 |
2006-10-10 |
Tanox, Inc. |
Bispecific molecules cross-linking ITIM and ITAM for therapy
|
EP2281840A3
(en)
|
2000-10-10 |
2012-05-23 |
Genentech, Inc. |
Inhibition of complement C5 activation for the treatment and prevention of delayed xenograft or acute vascular rejection
|
EP1355671A2
(en)
*
|
2000-11-30 |
2003-10-29 |
Nektar Therapeutics Al, Corporation |
Water-soluble polymer conjugates of triazine derivatives
|
US7829084B2
(en)
|
2001-01-17 |
2010-11-09 |
Trubion Pharmaceuticals, Inc. |
Binding constructs and methods for use thereof
|
EP3372243A1
(en)
|
2001-08-17 |
2018-09-12 |
Genentech, Inc. |
Complement pathway inhibitors binding to c5 and c5a without preventing formation of c5b
|
US7320789B2
(en)
|
2001-09-26 |
2008-01-22 |
Wyeth |
Antibody inhibitors of GDF-8 and uses thereof
|
US7674769B2
(en)
*
|
2001-10-15 |
2010-03-09 |
Novartis Vaccines And Diagnostics, Inc. |
Treatment of severe pneumonia by administration of tissue factor pathway inhibitor (TFPI)
|
AU2003216345A1
(en)
|
2002-02-21 |
2003-09-09 |
Wyeth |
Follistatin domain containing proteins
|
CA2511486A1
(en)
*
|
2002-12-30 |
2004-07-22 |
Angiotech International Ag |
Tissue reactive compounds and compositions and uses thereof
|
EP1594459B1
(en)
*
|
2002-12-30 |
2010-02-17 |
Angiotech International Ag |
Drug delivery from rapid gelling polymer composition
|
EP2184298A1
(en)
|
2003-03-14 |
2010-05-12 |
Wyeth a Corporation of the State of Delaware |
Antibodies against human IL-21 receptor and uses therefor
|
WO2005044294A2
(en)
|
2003-11-04 |
2005-05-19 |
Chiron Corporation |
Method of therapy for cancers expressing the cd40 antigen
|
US20070098718A1
(en)
|
2003-11-04 |
2007-05-03 |
Chiron |
Methods of therapy for b cell-related cancers
|
EP1682177B8
(en)
|
2003-11-04 |
2010-09-01 |
Novartis Vaccines and Diagnostics, Inc. |
Use of antagonist anti-cd40 antibodies for treatment of chronic lymphocytic leukemia
|
EP1680141B8
(en)
|
2003-11-04 |
2011-01-12 |
Novartis Vaccines and Diagnostics, Inc. |
Methods of therapy for solid tumors expressing the cd40 cell-surface antigen
|
CA2544951A1
(en)
|
2003-11-04 |
2005-05-19 |
Chiron Corporation |
Use of antagonist anti-cd40 monoclonal antibodies for treatment of multiple myeloma
|
PL1704166T3
(pl)
|
2004-01-07 |
2015-10-30 |
Novartis Vaccines & Diagnostics Inc |
Przeciwciała monoklonalne swoiste względem M-CSF i ich zastosowania
|
US20050169970A1
(en)
*
|
2004-02-02 |
2005-08-04 |
Unilever Bestfoods, North America |
Food composition with fibers
|
AU2005244249A1
(en)
*
|
2004-03-17 |
2005-11-24 |
Novartis Vaccines And Diagnostics, Inc. |
Treatment of severe community-acquired pneumonia by admistration of tissue factor pathway inhibitor (TFPI)
|
BRPI0510477B1
(pt)
|
2004-04-28 |
2023-01-17 |
Angiotech Biomaterials Corporation |
Método para formar um gel e dispositivo para uso em aplicações médicas
|
WO2006034128A2
(en)
|
2004-09-17 |
2006-03-30 |
Angiotech Biomaterials Corporation |
Multifunctional compounds for forming crosslinked biomaterials and methods of preparation and use
|
EP2842571A1
(en)
|
2004-11-30 |
2015-03-04 |
Celldex Therapeutics, Inc. |
Antibodies directed to GPNMB and uses thereof
|
CA2589860A1
(en)
*
|
2005-01-24 |
2006-08-03 |
Amgen Inc. |
Humanized anti-amyloid antibody
|
IL296666A
(en)
|
2005-03-23 |
2022-11-01 |
Genmab As |
Antibodies against cd38 for treatment of multiple myeloma
|
US20060269556A1
(en)
*
|
2005-04-18 |
2006-11-30 |
Karl Nocka |
Mast cell activation using siglec 6 antibodies
|
NZ589687A
(en)
*
|
2005-07-21 |
2012-09-28 |
Genmab As |
Potency assays for antibody drug substance binding to an FC receptor
|
EP2277916A3
(en)
*
|
2005-07-28 |
2011-04-27 |
Novartis AG |
Use of antibody to M-CSF
|
US8652469B2
(en)
*
|
2005-07-28 |
2014-02-18 |
Novartis Ag |
M-CSF-specific monoclonal antibody and uses thereof
|
WO2007068255A1
(en)
|
2005-12-15 |
2007-06-21 |
Genmab A/S |
Use of effector-function-deficient antibodies for treatment of auto-immune diseases
|
TW200744634A
(en)
|
2006-02-21 |
2007-12-16 |
Wyeth Corp |
Methods of using antibodies against human IL-22
|
TWI417301B
(zh)
|
2006-02-21 |
2013-12-01 |
Wyeth Corp |
對抗人類介白素-22(il-22)之抗體及其用途
|
JP2009529915A
(ja)
|
2006-03-20 |
2009-08-27 |
ゾーマ テクノロジー リミテッド |
ガストリン物質に対して特異的なヒト抗体および方法
|
US20100196377A1
(en)
|
2006-04-13 |
2010-08-05 |
Jantapour Mary J |
Methods of treating, diagnosing or detecting cancer
|
TWI395754B
(zh)
|
2006-04-24 |
2013-05-11 |
Amgen Inc |
人類化之c-kit抗體
|
ES2531933T3
(es)
|
2006-06-30 |
2015-03-20 |
Novo Nordisk A/S |
Anticuerpos anti-NKG2A y usos de los mismos
|
RU2009107707A
(ru)
|
2006-08-04 |
2010-09-10 |
Новартис АГ (CH) |
СПЕЦИФИЧНОЕ К EphB3 АНТИТЕЛО И ЕГО ПРИМЕНЕНИЕ
|
NZ574138A
(en)
|
2006-08-18 |
2012-01-12 |
Xoma Technology Ltd |
Prlr-specific antibody and uses thereof
|
EP2494988B1
(en)
|
2006-12-07 |
2015-09-30 |
Novartis AG |
Antagonist antibodies against EPHB3
|
GB0700133D0
(en)
|
2007-01-04 |
2007-02-14 |
Humabs Llc |
Human cytomegalovirus neutralising antibodies and use thereof
|
TW201307390A
(zh)
*
|
2007-02-02 |
2013-02-16 |
Amgen Inc |
海帕西啶(hepcidin)、海帕西啶拮抗劑及使用方法
|
JP2010521180A
(ja)
|
2007-03-14 |
2010-06-24 |
ノバルティス アーゲー |
癌を処置、診断または検出するためのapcdd1阻害剤
|
ES2483942T5
(es)
|
2007-12-14 |
2017-02-06 |
Novo Nordisk A/S |
Anticuerpos contra NKG2D humano y usos de los mismos
|
EP2261254A3
(en)
|
2007-12-21 |
2011-04-13 |
Amgen, Inc |
Anti-amyloid antibodies and uses thereof
|
JP5774312B2
(ja)
|
2008-01-24 |
2015-09-09 |
ノボ・ノルデイスク・エー/エス |
ヒト化抗ヒトnkg2aモノクローナル抗体
|
JP5701064B2
(ja)
|
2008-01-25 |
2015-04-15 |
アムジエン・インコーポレーテツド |
フェロポーチン抗体およびその使用方法
|
EP2294087B1
(en)
|
2008-05-01 |
2014-05-14 |
Amgen, Inc. |
Anti-hepcidin antibodies and methods of use
|
AU2009246166B2
(en)
|
2008-05-15 |
2014-09-18 |
Tetherex Pharmaceuticals Corporation |
Anti-PSGL-1 antibodies and methods of identification and use
|
BRPI0822989A2
(pt)
|
2008-07-16 |
2018-05-29 |
Humabs Llc |
anticorpos de neutralização de citomegalovíorus humano e uso dos mesmos
|
MX343250B
(es)
|
2008-07-16 |
2016-10-31 |
Inst For Res In Biomedicine |
Anticuerpos neutralizantes de citomegalovirus humano y uso de los mismos.
|
WO2010010466A2
(en)
*
|
2008-07-25 |
2010-01-28 |
Institute For Research In Biomedicine |
Neutralizing anti-influenza a virus antibodies and uses thereof
|
US8871207B2
(en)
|
2008-07-25 |
2014-10-28 |
Humabs, LLC |
Neutralizing anti-influenza A virus antibodies and uses thereof
|
AU2009290091A1
(en)
*
|
2008-09-08 |
2010-03-11 |
Ottawa Hospital Research Institute |
Periostin-induced pancreatic regeneration
|
CA2739551C
(en)
|
2008-10-13 |
2019-03-05 |
Institute For Research In Biomedicine |
Dengue virus neutralizing antibodies and uses thereof
|
UA109633C2
(uk)
|
2008-12-09 |
2015-09-25 |
|
Антитіло людини проти тканинного фактора
|
EP2408814B1
(en)
|
2009-03-20 |
2018-11-21 |
Amgen Inc. |
Carrier immunoglobulins and uses thereof
|
AU2010298036B2
(en)
|
2009-09-25 |
2015-05-21 |
Xoma Technology Ltd. |
Screening methods
|
US8926976B2
(en)
|
2009-09-25 |
2015-01-06 |
Xoma Technology Ltd. |
Modulators
|
EP2501407A1
(en)
|
2009-11-20 |
2012-09-26 |
Amgen Inc. |
Anti-orai1 antigen binding proteins and uses thereof
|
WO2011092593A2
(en)
|
2010-01-20 |
2011-08-04 |
Institute For Research In Biomedicine |
Hiv-1 neutralizing antibodies and uses thereof
|
NZ602294A
(en)
|
2010-03-10 |
2015-04-24 |
Genmab As |
Monoclonal antibodies against c-met
|
CN103153339B
(zh)
|
2010-05-27 |
2021-05-04 |
根马布股份公司 |
针对her2表位的单克隆抗体
|
NZ604003A
(en)
|
2010-05-27 |
2015-04-24 |
Genmab As |
Monoclonal antibodies against her2
|
PT2580243T
(pt)
|
2010-06-09 |
2020-01-22 |
Genmab As |
Anticorpos contra cd38 humana
|
NZ604718A
(en)
|
2010-06-15 |
2015-01-30 |
Genmab As |
Human antibody drug conjugates against tissue factor
|
EP2619226B1
(en)
|
2010-09-22 |
2018-09-12 |
Amgen Inc. |
Carrier immunoglobulins and uses thereof
|
AR083847A1
(es)
|
2010-11-15 |
2013-03-27 |
Novartis Ag |
Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
|
AU2011335551B2
(en)
|
2010-12-02 |
2016-10-06 |
Bionor Immuno As |
Peptide scaffold design
|
EP3222635A1
(en)
|
2010-12-21 |
2017-09-27 |
Selexys Pharmaceuticals Corporation |
Anti-p-selectin antibodies and methods of their use and identification
|
EA034031B1
(ru)
|
2011-01-06 |
2019-12-20 |
Бионор Иммуно Ас |
Димерный пептид для индуцирования иммунного ответа против hiv и его применение
|
US9499610B2
(en)
|
2011-04-08 |
2016-11-22 |
H. Lundbeck A/S |
Antibodies specific to pyroglutamated Aβ
|
JP6177231B2
(ja)
|
2011-04-20 |
2017-08-09 |
ゲンマブ エー/エス |
Her2に対する二重特異性抗体
|
EP4520771A3
(en)
|
2011-04-20 |
2025-07-16 |
Genmab A/S |
Bispecifc antibodies against her2
|
JP6363948B2
(ja)
|
2011-06-03 |
2018-07-25 |
ゾーマ テクノロジー リミテッド |
TGF−βに特異的な抗体
|
UA117901C2
(uk)
|
2011-07-06 |
2018-10-25 |
Ґенмаб Б.В. |
Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
|
JP6035332B2
(ja)
|
2011-07-18 |
2016-11-30 |
インスティテュート・フォー・リサーチ・イン・バイオメディシンInstitute For Research In Biomedicine |
A型インフルエンザウイルス中和抗体及びその使用法
|
WO2013140247A1
(en)
|
2012-03-20 |
2013-09-26 |
Humabs Biomed Sa |
Antibodies that neutralize rsv, mpv and pvm and uses thereof
|
JP6310909B2
(ja)
|
2012-06-06 |
2018-04-11 |
ビオノール イミュノ エーエスBionor Immuno As |
免疫原及び投薬反応物として使用するためのウイルスタンパク質に由来するペプチド
|
SG10201605703TA
(en)
|
2012-07-06 |
2016-09-29 |
Genmab Bv |
Dimeric protein with triple mutations
|
EP3632462A1
(en)
|
2012-07-06 |
2020-04-08 |
Genmab B.V. |
Dimeric protein with triple mutations
|
UA105278C2
(ru)
|
2012-09-06 |
2014-04-25 |
Інститут Біології Клітини Нан України |
Способ получения каталитически активных антител (абзимов) с сиалидазной активностью
|
WO2014108198A1
(en)
|
2013-01-10 |
2014-07-17 |
Genmab B.V. |
Human igg1 fc region variants and uses thereof
|
TWI682941B
(zh)
|
2013-02-01 |
2020-01-21 |
美商再生元醫藥公司 |
含嵌合恆定區之抗體
|
SG11201506335YA
(en)
|
2013-03-14 |
2015-09-29 |
Regeneron Pharma |
Apelin fusion proteins and uses thereof
|
MX359794B
(es)
|
2013-03-15 |
2018-10-10 |
Intrinsic Lifesciences Llc |
Anticuerpos anti-hepcidina y usos de los mismos.
|
HRP20201373T1
(hr)
|
2013-10-02 |
2020-11-27 |
Medimmune, Llc |
Neutralizacijska protutijela protiv influence a i njihova upotreba
|
WO2015109264A1
(en)
|
2014-01-17 |
2015-07-23 |
Cedars-Sinai Medical Center |
Receptor targeting constructs and uses thereof
|
WO2016007414A1
(en)
|
2014-07-08 |
2016-01-14 |
New York University |
Tau imaging ligands and their uses in the diagnosis and treatment of tauopathy
|
ES2774428T3
(es)
|
2014-07-11 |
2020-07-21 |
Genmab As |
Anticuerpos que se unen a AXL
|
BR112017000640A2
(pt)
|
2014-07-15 |
2017-11-14 |
Lanzavecchia Antonio |
anticorpos neutralizantes do vírus influenza b e suas utilizações
|
US11786469B2
(en)
|
2014-07-22 |
2023-10-17 |
Cheolhee WON |
Silica nanoparticle composition for delivering bioactive material or protein such as a human proteasome
|
CA2955007C
(en)
|
2014-07-24 |
2023-04-11 |
Genentech, Inc. |
Methods of conjugating an agent to a thiol moiety in a protein that contains at least one trisulfide bond
|
AU2015321462B2
(en)
|
2014-09-22 |
2020-04-30 |
Intrinsic Lifesciences Llc |
Humanized anti-hepcidin antibodies and uses thereof
|
US20170296650A1
(en)
|
2014-10-08 |
2017-10-19 |
Novartis Ag |
Combination of human cytomegalovirus neutralizing antibodies
|
RU2744841C2
(ru)
|
2014-10-24 |
2021-03-16 |
Астразенека Аб |
Комбинация
|
WO2016073647A2
(en)
|
2014-11-04 |
2016-05-12 |
University Of Southern California |
COMPOSITIONS AND METHODS FOR TREATING HIF-1alpha OVER-EXPRESSING CANCERS
|
WO2016075546A2
(en)
|
2014-11-14 |
2016-05-19 |
Antonio Lanzavecchia |
Antibodies that neutralize ebola virus and uses thereof
|
EP3220947B1
(en)
|
2014-11-18 |
2020-10-28 |
Humabs Biomed S.A. |
Antibodies that potently neutralize rabies virus and other lyssaviruses and uses thereof
|
EP3916017A1
(en)
|
2014-12-22 |
2021-12-01 |
PD-1 Acquisition Group, LLC |
Anti-pd-1 antibodies
|
CA2981312C
(en)
|
2015-03-30 |
2023-09-26 |
Regeneron Pharmaceuticals, Inc. |
Heavy chain constant regions with reduced binding to fc gamma receptors
|
US10441644B2
(en)
|
2015-05-05 |
2019-10-15 |
The Regents Of The University Of California |
H3.3 CTL peptides and uses thereof
|
ES2842849T3
(es)
|
2015-05-05 |
2021-07-15 |
Univ California |
Péptidos CTL H3.3 y usos de los mismos
|
US20160347848A1
(en)
|
2015-05-28 |
2016-12-01 |
Medimmune Limited |
Therapeutic combinations and methods for treating neoplasia
|
DK3303384T3
(da)
|
2015-06-01 |
2021-10-18 |
Medimmune Llc |
Neutraliserende anti-influenza-bindingsmolekyler og anvendelser deraf
|
WO2016207402A1
(en)
|
2015-06-26 |
2016-12-29 |
Institute For Research In Biomedicine |
Proteins comprising a mutated lair-1 fragment and uses thereof
|
JP6892431B2
(ja)
|
2015-07-10 |
2021-06-23 |
ゲンマブ エー/エス |
癌治療用のaxl特異的抗体−薬物コンジュゲート
|
GB201512215D0
(en)
|
2015-07-13 |
2015-08-19 |
Lundbeck & Co As H |
Agents,uses and methods
|
GB201512203D0
(en)
|
2015-07-13 |
2015-08-19 |
Lundbeck & Co As H |
Agents,uses and methods
|
JO3711B1
(ar)
|
2015-07-13 |
2021-01-31 |
H Lundbeck As |
أجسام مضادة محددة لبروتين تاو وطرق استعمالها
|
US10358503B2
(en)
|
2015-08-13 |
2019-07-23 |
New York University |
Antibody-based molecules selective for the {P}Ser404 epitope of Tau and their uses in the diagnosis and treatment of tauopathy
|
JP6913078B2
(ja)
|
2015-08-13 |
2021-08-04 |
ニューヨーク・ユニバーシティ |
タウの短縮型Asp421エピトープに特異的な、抗体を基にした分子、ならびにタウ異常症の診断および治療におけるそれらの使用
|
WO2017059878A1
(en)
|
2015-10-07 |
2017-04-13 |
Humabs Biomed Sa |
Antibodies that potently neutralize hepatitis b virus and uses thereof
|
WO2017062966A1
(en)
|
2015-10-09 |
2017-04-13 |
Florida State University Research Foundation, Inc. |
Antibodies specific for 4,6-diamino-5-(formyulamino) pyrimidine and uses thereof
|
UY36990A
(es)
|
2015-11-21 |
2017-11-30 |
Fundació Privada Inst De Recerca De La Sida-Caixa (Irsicaixa) |
Derivados de anticuerpos contra el vih con actividad dual antiviral e inmunomodulatoria
|
EP3402513A4
(en)
|
2016-01-13 |
2019-10-23 |
Medlmmune, LLC |
METHOD FOR THE TREATMENT OF INFLUENZA A
|
CN116041504A
(zh)
|
2016-07-12 |
2023-05-02 |
H.隆德贝克有限公司 |
特异性针对过度磷酸化τ蛋白的抗体及其使用方法
|
WO2018010789A1
(en)
|
2016-07-13 |
2018-01-18 |
Humabs Biomed Sa |
Novel antibodies specifically binding to zika virus epitopes and uses thereof
|
WO2018067754A1
(en)
|
2016-10-04 |
2018-04-12 |
Fairbanks Pharmaceuticals, Inc. |
Anti-fstl3 antibodies and uses thereof
|
BR112019008702A2
(pt)
|
2016-11-01 |
2019-07-16 |
Genmab B.V. |
polipeptídeo, método de diminuição de uma função fc efetora de um polipeptídeo, composição, método de tratamento, kit de partes, e, uso de um polipeptídeo ou composição.
|
CA3043651A1
(en)
|
2016-11-15 |
2018-05-24 |
H. Lundbeck A/S |
Agents, uses and methods for the treatment of synucleinopathy
|
EP3329905A1
(en)
|
2016-12-05 |
2018-06-06 |
Nuritas Limited |
Topical cosmetic compositions comprising an oligopeptide against anti-aging of the skin
|
EP3329930A1
(en)
|
2016-12-05 |
2018-06-06 |
Nuritas Limited |
Pharmaceuctical compositions
|
US10729636B2
(en)
|
2016-12-05 |
2020-08-04 |
Nuritas Limited |
Compositions comprising peptide WKDEAGKPLVK
|
MA47019A
(fr)
|
2016-12-16 |
2021-04-21 |
H Lundbeck As |
Agents, utilisations et procédés
|
US10364286B2
(en)
|
2016-12-22 |
2019-07-30 |
H. Lundbeck A/S |
Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation
|
US10995137B2
(en)
|
2017-01-04 |
2021-05-04 |
H. Lundbeck A/S |
Antibodies specific for hyperphosphorlated tau for the treatment of ocular diseases
|
WO2018143787A1
(ko)
|
2017-02-06 |
2018-08-09 |
주식회사 레모넥스 |
생리활성물질 전달체
|
KR20180091768A
(ko)
|
2017-02-06 |
2018-08-16 |
주식회사 레모넥스 |
생리활성물질 전달체
|
CN118085055A
(zh)
|
2017-04-19 |
2024-05-28 |
生物医学研究所 |
作为疫苗及新疟疾疫苗和抗体结合靶标的疟原虫子孢子npdp肽
|
AU2018266847A1
(en)
|
2017-05-10 |
2019-11-28 |
Albajuna Therapeutics, S.L. |
Fc-fusion protein derivatives with high dual HIV antiviral and immunomodulatory activity
|
US10894833B2
(en)
|
2017-07-20 |
2021-01-19 |
H. Lundbeck A/S |
Agents, uses and methods for treatment
|
CA3070446A1
(en)
|
2017-07-25 |
2019-01-31 |
Immutics, Inc. |
Treating cancer by blocking the interaction of tim-3 and its ligand
|
WO2019042555A1
(en)
|
2017-08-31 |
2019-03-07 |
Humabs Biomed Sa |
MULTISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO ZIKA VIRUS EPITOPES AND USES THEREOF
|
US11530132B2
(en)
|
2017-09-05 |
2022-12-20 |
Lemonex Inc. |
Composition comprising porous silica particles carrying a cell fate modulating factor
|
US20210107988A1
(en)
|
2018-01-24 |
2021-04-15 |
Genmab B.V. |
Polypeptide variants and uses thereof
|
EP3752195A4
(en)
|
2018-02-14 |
2021-11-17 |
Viela Bio, Inc. |
ANTIBODIES DIRECTED AGAINST FELIN MCDONOUGH SARCOMA TYROSINE KINASE 3 RECEPTOR LIGAND (FMS) (FLT3L) AND THEIR USES FOR THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES
|
KR20210005051A
(ko)
|
2018-04-30 |
2021-01-13 |
다케다 야쿠힌 고교 가부시키가이샤 |
카나비노이드 수용체 유형 1 (cb1) 결합 단백질들과 이의 용도
|
US20210238229A1
(en)
|
2018-06-14 |
2021-08-05 |
University College Cork - National University Of Ireland, Cork |
Peptide for disease treatment
|
WO2020021061A1
(en)
|
2018-07-26 |
2020-01-30 |
Pieris Pharmaceuticals Gmbh |
Humanized anti-pd-1 antibodies and uses thereof
|
CA3121004A1
(en)
|
2018-12-19 |
2020-06-25 |
Humabs Biomed Sa |
Antibodies that neutralize hepatitis b virus and uses thereof
|
CN116063520A
(zh)
|
2019-01-30 |
2023-05-05 |
真和制药有限公司 |
抗gal3抗体及其用途
|
WO2020176771A1
(en)
|
2019-02-27 |
2020-09-03 |
Ionis Pharmaceuticals, Inc. |
Modulators of malat1 expression
|
AU2020248645A1
(en)
|
2019-03-27 |
2021-10-28 |
Tigatx, Inc. |
Engineered IgA antibodies and methods of use
|
SG11202110610VA
(en)
|
2019-04-09 |
2021-10-28 |
Abcuro Inc |
Killer cell lectin-like receptor subfamily g member 1 (klrg1) depleting antibodies
|
EP3783012A1
(en)
|
2019-08-20 |
2021-02-24 |
Nuritas Limited |
An antimicrobial peptide
|
US20220287347A1
(en)
|
2019-08-20 |
2022-09-15 |
Nuritas Limited |
Peptides for treating muscle atrophy
|
MX2022002231A
(es)
|
2019-08-29 |
2022-03-22 |
Vir Biotechnology Inc |
Composiciones de anticuerpos y metodos para tratar la infeccion por el virus de la hepatitis b.
|
AU2020370733A1
(en)
|
2019-10-22 |
2022-05-05 |
Nuritas Limited |
Treatment of non-alcoholic fatty liver disease
|
EP3862014A1
(en)
|
2020-02-07 |
2021-08-11 |
Nuritas Limited |
Treatment of panx1 associated diseases
|
US20230109142A1
(en)
|
2020-02-14 |
2023-04-06 |
Immunor As |
Corona virus vaccine
|
US12281166B2
(en)
|
2020-05-26 |
2025-04-22 |
Truebinding, Inc. |
Methods of treating inflammatory diseases by blocking Galectin-3
|
BR112022026316A2
(pt)
|
2020-06-24 |
2023-03-07 |
Vir Biotechnology Inc |
Anticorpos neutralizantes do vírus da hepatite b engenheirados e usos dos mesmos
|
CN116635426A
(zh)
|
2021-01-08 |
2023-08-22 |
北京韩美药品有限公司 |
特异性结合cd47的抗体及其抗原结合片段
|
US20250277044A1
(en)
|
2021-01-08 |
2025-09-04 |
Beijing Hanmi Pharmaceutical Co., Ltd. |
Antibody specifically binding to 4-1bb and antigen-binding fragment of antibody
|
KR20230129483A
(ko)
|
2021-01-08 |
2023-09-08 |
베이징 한미 파마슈티컬 컴퍼니 리미티드 |
Pd-l1과 특이적으로 결합하는 항체 및 그 항원 결합단편
|
JP2024504167A
(ja)
|
2021-01-26 |
2024-01-30 |
ヴィア・バイオテクノロジー・インコーポレイテッド |
B型肝炎ウイルス感染を処置するための抗体組成物および方法
|
WO2022204529A1
(en)
|
2021-03-26 |
2022-09-29 |
Abcuro, Inc. |
Anti-klrg1 antibodies
|
WO2022204514A1
(en)
|
2021-03-26 |
2022-09-29 |
Abcuro, Inc. |
Anti-klrg1 antibodies
|
WO2022212836A1
(en)
|
2021-04-01 |
2022-10-06 |
Pyxis Oncology, Inc. |
Gpnmb antibodies and methods of use
|
JP2024514194A
(ja)
|
2021-04-14 |
2024-03-28 |
ユニバーシティ・カレッジ・コークーナショナル・ユニバーシティ・オブ・アイルランド,コーク |
変形性関節症の治療に使用するためのpsg1
|
EP4322983A1
(en)
|
2021-04-14 |
2024-02-21 |
University College Cork-National University of Ireland Cork |
Treatment of cerebrovascular events and neurological disorders
|
CA3227742A1
(en)
|
2021-07-26 |
2023-02-02 |
Abcuro, Inc. |
Killer cell lectin-like receptor subfamily g member 1 (klrg1) depleting antibodies
|
WO2023105281A1
(en)
|
2021-12-11 |
2023-06-15 |
Fundaciò Privada Institut De Recerca De La Sida-Caixa |
Soluble tigit recombinant proteins
|
CN117589996A
(zh)
|
2022-08-09 |
2024-02-23 |
深圳智源生物医药有限公司 |
强毒性淀粉样蛋白寡聚体的诊断用途
|
CN117586388A
(zh)
|
2022-08-09 |
2024-02-23 |
深圳智源生物医药有限公司 |
改进的β淀粉样蛋白寡聚体特异性结合抗体
|
WO2024078729A1
(en)
|
2022-10-14 |
2024-04-18 |
University College Cork - National University Of Ireland, Cork |
Placenta expressed proteins for use in the treatment of tendon injury
|
WO2025147544A1
(en)
|
2024-01-02 |
2025-07-10 |
Abcuro, Inc. |
Methods of treating inclusion body myositis (ibm)
|